Approvals received from Bpifrance and Société Générale for a total of EUR 10 million in non-dilutive financing in the form of a State- Guarantee d Loan (PGE Loan) Proceeds expected to extend Company’s cash horizon to end of 2021 LYON, France and CAMBRIDGE, Mass., Nov.
LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , t oday announced that it will host a Third Quarter
LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appoint ment of Dr.
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)
Conference call and webcast on Tuesday, September 22 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 90% of the planned 500 patients enrolled Fast-Track designation granted by U.S. FDA Interim superiority analysis expected in Q1 2021 ; final
LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the "Company"), today announced the implementation of an
LYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter
More than 450 of the planned ~ 500 patients enrolled Interim superiority analysis expected around year-end 2020 Call with KOL Dr. Manuel Hidalgo on September 29, 2020 at 10:00 am ET LYON, France and CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a
LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
LYON, France, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States